Phase 2 N=165 Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
Peptic Ulcer
Primary: Recurrent Peptic Ulcer — 1; 9 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=101 Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
Peptic Ulcer
Primary: Number of Participants With Ulcer Recurrence — 1; 7 participants
N/A N=60 Proton Pump Inhibitors and Dysbiosis in Cirrhosis
Cirrhosis · Healthy
Primary: Number of Patients With Overgrowth of Oral Microbiota in Their Stool After PPI Therapy Withdrawal or Initiation — 45; 15 Participants
Phase 3 N=63 Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)
Human Experimentation
Primary: Achievement of Sustained Difference in Inhibition of Intragastric Acidity Based on Median pH Values Between the Two Active Study Treatments at Steady-state on Day 7…
Phase 2 N=17 Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations
Cystic Fibrosis
Primary: Time to First Pulmonary Exacerbation — NA; NA Weeks
N/A N=63 Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy
GERD
Primary: Number of Impedance Episodes Following PPI and Placebo — 47; 53 number of episodes
N/A N=220,306 Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program
Proton Pump Inhibitors
Primary: PPI Prescribing (H1) — 73.69; 72.66 percentage of days on PPI
Phase 2 N=19 Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)
Pancreatic Insufficiency · Cystic Fibrosis
Primary: Coefficient of Fat Absorption — 80; 77 % fat absorption
Phase 4 N=106 PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
Liver Cirrhosis · Hypertension, Portal
Primary: Variceal Bleeding Events — 3; 3 Participants
Phase 4 N=64 Symptom Control Satisfaction With Proton Pump Inhibitor Regimen
Heartburn
Primary: Symptom Frequency and Severity/Distress Scores From Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) (Overall) — 8.5; 5.2; 2.2; 1.0 score on a scale
Phase 4 N=123 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
Helicobacter Pylori Infection
Primary: Urea Breath Test Result (DOB > 5 is Positive)After Different Time Periods From When PPI (Proton Pump Inhibitor) Was Stopped. — 1; 3; 1; 0 participants
Phase 1 N=12 Effect of a Proton Pump Inhibitor on the PK of Tepotinib
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Tepotinib in Treatment A and Treatment C — 21722; 23649…
Phase 1 N=64 Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) — 94.37; 43.84; 106.35; 51.65 ng/mL
Phase 1 N=20 PPI and Clopidogrel Response
Drug Interaction
Primary: Platelet Function as Assessed by the P2Y12 Reactivity Index — 56.1; 61.6; 56; 61 Percentage of platelet reactivity index
N/A N=61,864 Risk of Cancer Among Pantoprazole Users
Esophagitis
Primary: Incidence Rate of Gastric Cancer — 19.88; 23.73 incidence per 100000 person-years
N/A N=8,616 Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS)
Erosive Gastroesophageal Reflux Disease · Non-Erosive Reflux Disease
Primary: Assessment of the Severity of Sleep Disturbances — 13.8; 77.4; 38.2; 20.0 percentage of participants
N/A N=185 Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing
Gastroesophageal Reflux Disease
Primary: Reflux Disease Questionnaire (RDQ) — -0.387; -0.296 score on a scale — p=0.78
Phase 2 N=480 Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease
Primary: Change From Baseline in Percent Regurgitation-Free Days Over Weeks 5-8 — 36.96; 43.01; 44.37; 38.79 percentage of days — p=0.128
Phase 4 N=55 Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment
Heartburn
Primary: Number of Participants With Relief of 24 Hour Heartburn and Without Relief of 24 Hour Heartburn — 7; 10; 0; 9 participants
Phase 3 N=344 Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)
Gastroesophageal Reflux
Primary: Change From Baseline in Average Daily Frequency of Regurgitation (Double-blind Phase/ Baseline Observation Carried Forward) — -0.8; -0.8; -1.6; -1.2 frequency of…
Phase 3 N=337 Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
Refractory Reflux Esophagitis
Primary: Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N) — 58.8; 78.4; 77.0 Percentage of…
Phase 4 N=30 Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?
Inflammation · Barrett's Esophagus
Primary: Change in Inflammation Biomarker Tissue PGE2 Level — 1.35; -0.02; 1.19; -0.06 nanograms/gram of tissue — p=0.30
Phase 3 N=402 Study of Acid Reflux in Asthma
Asthma · Lung Diseases · Lung Diseases, Obstructive
Primary: Episodes of Poor Asthma Control (EPAC) From Diary Cards, According to Definition That Did Not Include Use of Beta-agonists as a Criterion — 2.3; 2.5 events per person…
Phase 3 N=239 Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease
Gastroesophageal Reflux
Primary: Determination of Median Time to Sustained Partial Response as Defined by Reduction in Likert Severity Scale Used to Assess Pain Associated With Heartburn in the Patient…
Phase 4 N=337 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
Gastroesophageal Reflux Disease
Primary: Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment — -3.44 Days per week with symptoms
Phase 4 N=40 Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression
Healthy
Primary: Mean Percent Time That Gastric pH > 4.0 on Day 5 — 36.8; 45.7 percent time gastric pH exceeds 4.0 — p=< 0.0001
N/A N=1,045 Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders
Sleep Disorders · Non-Erosive Reflux Disease · Gastroesophageal Reflux Disease
Primary: Patient's Assessment of Stanford Sleepiness Scale for the Last 24 Hours (Diaries) — 2.94; 2.62; 2.28; 2.03 Units on a scale
Phase 2 N=73 Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients
Indigestion
Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants
Phase 4 N=66 Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Hypothyroidism;Postablative
Primary: Thyroid Stimulating Hormone (TSH) — -0.676 mIU/L — p=<0.0001
Phase 2 N=100 Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor
Acute Kidney Injury
Primary: Area Under the Curve (AUC) of Urinary Kidney Injury Biomarker Kidney Injury Molecule-1 (KIM-1) Above Baseline Within 24 Hours Postoperatively — 51.4; 52.3 ng*h/mL